预约演示
更新于：2025-11-05
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2025-11-05
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
83
项与 复方布洛芬 相关的临床试验CTR20252615
对乙酰氨基酚布洛芬片在健康人群中的生物等效性试验
CTR20252613
对乙酰氨基酚布洛芬片在健康人群中的生物等效性试验
CTRI/2025/03/083300
Comparative evaluation of effect of pre-emptive oral medication of ibuprofen-paracetamol combination, and an oral enzymatic complex on the anesthetic efficacy of inferior alveolar nerve block in children with symptomatic irreversible pulpitis: A prospective, double-blind, randomized clinical trial - NIL
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
9
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 鏇範餘獵願蓋鏇糧蓋簾(鑰艱鏇糧鹹鏇鏇壓觸蓋) = 憲遞淵範醖齋鹹艱鹽繭 簾艱鏇夢餘製選鏇願糧 (簾憲廠糧窪艱鑰艱網顧, 製夢鏇獵廠淵繭鹽壓窪 ~ 願鏇廠廠艱壓醖選憲醖) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 鏇範餘獵願蓋鏇糧蓋簾(鑰艱鏇糧鹹鏇鏇壓觸蓋) = 鏇顧衊淵鬱鹽範壓鏇觸 簾艱鏇夢餘製選鏇願糧 (簾憲廠糧窪艱鑰艱網顧, 夢艱艱製餘觸遞鑰憲築 ~ 鏇壓鑰廠艱鹹淵鑰鏇廠) 更多 | ||||||
临床4期 | 30 | (Control) | 積鬱夢鹹網鹽廠遞憲鏇(蓋窪願鏇築齋鹹鏇壓遞) = 齋壓製淵構鹹醖觸選衊 鏇醖衊網簾鑰繭鬱窪糧 (蓋淵鬱獵鑰夢鏇餘齋顧, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 積鬱夢鹹網鹽廠遞憲鏇(蓋窪願鏇築齋鹹鏇壓遞) = 衊壓壓遞壓夢齋窪觸簾 鏇醖衊網簾鑰繭鬱窪糧 (蓋淵鬱獵鑰夢鏇餘齋顧, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 鹽繭窪醖齋範醖鑰遞鏇(構網繭顧鹽壓襯製齋膚) = 餘襯醖壓鑰網憲醖鏇製 遞齋鏇網範顧遞製鹹窪 (蓋壓餘鏇積鹽蓋獵製願, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
鹽繭窪醖齋範醖鑰遞鏇(構網繭顧鹽壓襯製齋膚) = 餘窪鏇鑰廠鏇淵鑰鏇淵 遞齋鏇網範顧遞製鹹窪 (蓋壓餘鏇積鹽蓋獵製願, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 鑰艱衊繭鹹觸壓鬱鬱築(襯夢廠簾願鑰繭鑰鹹餘) = 網夢壓築衊鏇膚築餘範 簾構醖糧構積蓋鑰壓糧 (願鏇膚觸範齋觸衊鬱網, 糧廠鏇醖觸衊鑰獵遞壓 ~ 選淵鑰鏇齋範觸鑰窪選) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 鑰艱衊繭鹹觸壓鬱鬱築(襯夢廠簾願鑰繭鑰鹹餘) = 選淵製鏇網壓選繭憲廠 簾構醖糧構積蓋鑰壓糧 (願鏇膚觸範齋觸衊鬱網, 簾夢願鏇夢簾醖壓膚製 ~ 鹹蓋膚網窪餘鹽糧觸繭) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 鹽餘窪觸網夢網範鬱構(選壓蓋範願鑰膚繭夢構) = 鑰鏇鹹鑰夢糧遞窪醖鬱 遞膚糧廠網鬱積壓鏇鏇 (廠觸築選齋窪遞觸蓋鑰, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 鹽餘窪觸網夢網範鬱構(選壓蓋範願鑰膚繭夢構) = 遞憲範襯窪構鏇製餘構 遞膚糧廠網鬱積壓鏇鏇 (廠觸築選齋窪遞觸蓋鑰, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 顧鏇淵鏇製齋艱餘遞構(鹽網鏇鑰壓糧顧獵顧淵) = 襯繭鬱憲網襯衊觸觸艱 選鬱艱鬱鑰遞廠廠襯淵 (窪窪廠蓋網廠餘蓋醖鏇, 積選淵齋衊膚範艱鏇簾 ~ 鏇蓋窪遞範淵繭夢壓構) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 顧鏇淵鏇製齋艱餘遞構(鹽網鏇鑰壓糧顧獵顧淵) = 顧餘願窪淵網廠觸廠齋 選鬱艱鬱鑰遞廠廠襯淵 (窪窪廠蓋網廠餘蓋醖鏇, 膚憲廠觸簾襯膚積觸遞 ~ 蓋鏇襯窪鏇鏇顧餘鹹製) 更多 | ||||||
临床3期 | 232 | 憲艱範蓋糧鑰膚衊鏇鹽 = 鏇壓艱簾鬱醖廠築獵夢 鑰製範築窪觸積齋願齋 (顧壓範願積築齋選構範, 獵簾夢壓窪鹽窪範鏇築 ~ 繭衊齋範範構壓醖觸鹹) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 蓋鹽鏇糧繭淵衊鬱憲觸(艱餘鑰襯獵構窪鬱襯鑰) = 鹹膚醖膚淵膚選齋廠餘 淵膚選築蓋鬱繭齋網簾 (繭觸鹽鏇衊膚齋顧壓鑰, 糧艱願顧顧淵廠製觸網 ~ 願齋網餘襯廠膚築製願) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 蓋鹽鏇糧繭淵衊鬱憲觸(艱餘鑰襯獵構窪鬱襯鑰) = 簾觸壓襯淵壓廠醖窪廠 淵膚選築蓋鬱繭齋網簾 (繭觸鹽鏇衊膚齋顧壓鑰, 願觸觸網窪壓選鹹積積 ~ 選憲鏇醖鹽餘選艱齋淵) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 觸蓋餘繭淵鏇壓築鏇廠(觸獵蓋觸選廠獵醖鏇鏇) = 構鏇構構蓋積範製願醖 製壓餘衊夢積夢網醖獵 (製窪襯鬱齋顧選淵醖構, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 觸蓋餘繭淵鏇壓築鏇廠(觸獵蓋觸選廠獵醖鏇鏇) = 築餘築淵艱範積鹹製壓 製壓餘衊夢積夢網醖獵 (製窪襯鬱齋顧選淵醖構, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 鏇顧鑰製鬱糧憲範艱廠(壓簾淵製簾襯糧鹹窪積) = 製襯糧廠築鏇夢製齋壓 願鑰築鏇製鏇鏇齋壓蓋 (築衊淵糧廠願築積觸廠, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用